Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: OTC nizatidine, Zantac 75

This article was originally published in The Tan Sheet

Executive Summary

OTC nizatidine, Zantac 75: Whitehall-Robins' nizatidine Rx-to-OTC switch is "approvable," FDA notified the company on Nov. 30. The agency's Nonprescription Drug and Gastrointestinal Drugs Advisory Committees recommended that nizatidine 75 b.i.d. be approved for prevention of meal-induced heartburn at a Sept. 28 meeting ("The Tan Sheet" Oct. 2, p. 13). Glaxo-Wellcome was informed on Oct. 23 by FDA that its heartburn remedy Zantac 75 is "approvable." The nonprescription ranitidine Rx-to-OTC switch received an advisory committee recommendation in July ("The Tan Sheet" July 17, p. 4). The product will be marketed by Warner Wellcome under a joint venture agreement with Glaxo...

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel